Multicenter Registry of Patients With Subarachnoid Hemorrhage (MEASURE)

The purpose of this registry is to collect detailed information on the characteristics, treatment, and outcomes of patients with a subarachnoid hemorrhage. This information will enable research aimed at improving the safety and effectiveness of current and future treatments. By studying these data, the investigators aim to identify which treatment strategies offer the best results and which factors are most important in the care of patients with a subarachnoid hemorrhage. The knowledge gained from this research will help improve patient care in the future.

Study Overview

• Status: Recruiting
• Conditions: Subarachnoid Hemorrhage, Spontaneous
• Intervention / Treatment: Other: None, observational study

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: P.B. van Wijngaarden, MD; Phone Number: +88 755 5555; Email: measure@umcutrecht.nl

Study Locations

• Netherlands
  • Gelderland
    • Nijmegen, Gelderland, Netherlands, 6525 GA
      • Recruiting
      • Radboud University Medical Center
      • Contact: H.D. Boogaarts, MD, PhD; Phone Number: +31243611111; Email: jeroen.boogaarts@radboudumc.nl
  • Limburg
    • Maastricht, Limburg, Netherlands, 6229 HX
      • Recruiting
      • Maastricht University Medical Center+
      • Contact: R.H.L. Haeren, MD, PhD; Phone Number: +31433876543; Email: roel.haeren@mumc.nl
  • North Brabant
    • Tilburg, North Brabant, Netherlands, 5022GC
      • Recruiting
      • Elisabeth-Tweesteden Hospital
      • Contact: P.J.P. Nachtergaele, MD, PhD; Phone Number: +31132210000; Email: p.nachtergaele@etz.nl
  • North Holland
    • Amsterdam, North Holland, Netherlands, 1105AZ
      • Recruiting
      • Amsterdam University Medical Center
      • Contact: D. Verbaan, PhD; Phone Number: +31205669111; Email: d.verbaan@amsterdamumc.nl
  • Overijssel
    • Zwolle, Overijssel, Netherlands, 8025 AB
      • Recruiting
      • Isala
      • Contact: M. Podlogar, MD, PhD; Phone Number: +31886245000; Email: m.podlogar@isala.nl
  • Provincie Groningen
    • Groningen, Provincie Groningen, Netherlands, 9713 GZ
      • Recruiting
      • University Medical Center Groningen
      • Contact: J.M.C. van Dijk, MD, PhD; Phone Number: +31503616161; Email: j.m.c.van.dijk@umcg.nl
  • South Holland
    • Rotterdam, South Holland, Netherlands, 3015 GD
      • Recruiting
      • Erasmus University Medical Center
      • Contact: V. Volovici, MD, PhD; Phone Number: +31107040704; Email: v.volovici@erasmusmc.nl
    • The Hague, South Holland, Netherlands, 2512 VA
      • Recruiting
      • Haaglanden Medical Center
      • Contact: W.A. Moojen, MD, PhD; Phone Number: +31889797900; Email: w.moojen@haaglandenmc.nl
  • Utrecht
    • Utrecht, Utrecht, Netherlands, 3584 CX
      • Recruiting
      • Utrecht University Medical Center
      • Contact: M.D.I. Vergouwen, MD, PhD; Phone Number: +3188755555; Email: m.d.i.vergouwen@umcutrecht.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with spontaneous subarachnoid hemorrhage

Description

Inclusion Criteria:

• Age ≥ 18 years
• Spontaneous subarachnoid hemorrhage with blood in the basal cisterns and/or major fissures on non-contrast head computed tomography (CT), or xanthochromia of cerebrospinal fluid confirmed by spectrophotometric analysis.

• Eligible etiologies/patterns:

  • Aneurysmal SAH
  • SAH from other intracranial vascular malformation (e.g. AVM, dural AVF)
  • Perimesencephalic SAH
  • Non-perimesencephalic angiogram negative SAH
  • SAH from intracranial artery dissection

Exclusion Criteria:

• Traumatic, neoplastic, infection related (except mycotic aneurysms), or iatrogenic SAH
• Isolated convexity SAH

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Spontaneous Subarachnoid Hemorrhage	Other: None, observational study; None, observational study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Modified Rankin Scale (mRS)	The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.	6 months ± 30 days after SAH

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
modified Rankin Scale (mRS)	The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.	18 months ± 30 days after SAH
Complications related to treatment of the ruptured aneurysm		Periprocedural
Complications related to SAH		During registry period (up to 18 months after SAH)
Degree of aneurysm occlusion	For endovascular treatment assessed by the modified Raymond Roy Classification	Up to 18 months after SAH
Newly found aneurysm or other vascular malformation at additional imaging in patients with non-perimesencephalic primary angiogram negative SAH		Up to 18 months after SAH
Patient reported outcomes (PROMS): SOS-SAH	The Questionnaire for the Screening of Symptoms in aneurysmal Subarachnoid Hemorrhage (SOS-SAH) is a disease-specific patient-reported outcome measure developed to screen for symptoms in patients after aSAH. It consists of 14 domains: cognitive abilities, hypersensitivity to stimuli, anxiety, depression, fatigue, social roles, personality change, language, vision, taste, smell, hearing, headache, and sexual function. It also includes a proxy measurement for use by family members to assess cognitive functioning and personality changes. External validation of the SOS-SAH is one of the objectives of this registry.	Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): Stroke Specific Quality of Life scale (SSQoL)	The Stroke Specific Quality of Life scale (SSQoL) assesses health-related quality of life, comprising 49 items across 12 domains. Items are rated on a 5-point Likert scale ranging from "total help needed" to "no help needed." Higher scores indicate better functioning.	Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): EuroQol 5-Dimension 5-Level (EQ-5D-5L)	The EuroQol 5-Dimension 5-Level (EQ-5D-5L) assesses general health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated on a 5-level severity scale. Three scoring methods are used: (1) the EQ-VAS, a Visual Analogue Scale ranging from 0 to 100 where higher scores indicate better self-rated health; (2) the EQ-5D-5L health state, coded as a 5-digit number ranging from 11111 (full health) to 55555 (worst health); and (3) the EQ-5D-5L index value, calculated using the Dutch tariff, where higher scores indicate better health-related quality of life.	Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): Hospital Anxiety and Depression Scale (HADS)	The Hospital Anxiety and Depression Scale (HADS) is a 14-item instrument comprising two subscales: one for anxiety and one for depression. Each subscale ranges from 0 to 21. Higher scores indicate greater symptom severity.	Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C)	The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C) is an instrument for identifying cognitive problems after stroke. It consists of 13 items addressing cognitive complaints, for each of which the respondent indicates whether the complaint is present or absent. The total score ranges from 0 to 13, where higher scores indicate more cognitive and emotional complaints.	Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): iMTA Medical Consumption Questionnaire (iMCQ)	The iMTA Medical Consumption Questionnaire (iMCQ) is a generic instrument that measures medical consumption, including hospitalization days, contacts with health care providers, and medication use.	Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): iMTA Productivity Cost Questionnaire (iPCQ)	The iMTA Productivity Cost Questionnaire (iPCQ) is a generic instrument designed to measure health-related productivity losses in paid and unpaid work.	Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C)	The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C) is an instrument for identifying cognitive problems after stroke. It consists of 15 items addressing cognitive and emotional complaints, for each of which the respondent indicates whether the complaint is present or absent. The total score ranges from 0 to 15, where higher scores indicate more cognitive complaints.	Up to 18 months ± 30 days after SAH
Amsterdam Cognition Scan (ACS)	The Amsterdam Cognition Scan is a web-based digital cognitive test battery of approximately 60 minutes, consisting of 7 tasks assessing attention, memory, processing speed, executive functioning, and psychomotor speed.	Up to 18 months ± 30 days after SAH

Collaborators and Investigators

• Sponsor: UMC Utrecht
• Collaborators: Radboud University Medical Center; University Medical Center Groningen; Maastricht University Medical Center; Erasmus Medical Center; Dutch Heart Foundation; Medical Center Haaglanden; Elisabeth-TweeSteden Ziekenhuis; Isala; The Dutch Brain Foundation; Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)

Study record dates

Study Major Dates

• Study Start (Actual): February 12, 2024
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): February 1, 2028

Study Registration Dates

• First Submitted: March 9, 2026
• First Submitted That Met QC Criteria: March 15, 2026
• First Posted (Actual): March 19, 2026

Study Record Updates

• Last Update Posted (Actual): March 19, 2026
• Last Update Submitted That Met QC Criteria: March 15, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Hemorrhage; Intracranial Hemorrhages; Pathological Conditions, Signs and Symptoms; Subarachnoid Hemorrhage; Investigative Techniques; Methods; Observation
• Other Study ID Numbers: 23U-0340

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Upon reasonable request: For each study using the data of this registry, analyses will be performed according to a predefined analysis plan with clearly defined statistical methods. These plans will be prepared prior to data analysis and in accordance with relevant reporting standards, such as the STROBE guideline. All data requests and accompanying statistical analysis plans will be reviewed by an independent research committee affiliated with CONTRAST-2 (the Data Access and Writing Committee) to ensure appropriate use of the registry data.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No